

Trimbow® (beclometasone dipropionate, formoterol, glycopyrronium) 172/5/9 pMDI recommended for use within NHS Scotland

- Beclometasone dipropionate/formoterol/glycopyrronium 172mcg / 5mcg / 9mcg pMDI has been accepted for use by the Scottish Medicines Consortium (SMC) as a maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and high dose of inhaled corticosteroid (ICS), and who experienced one or more asthma exacerbations in the previous year¹
- Beclometasone dipropionate/formoterol/glycopyrronium now offers an additional treatment choice of high dose ICS, LABA and long-acting muscarinic antagonist (LAMA) in a single inhaler to patients in Scotland¹

Manchester, UK, 8 August 2022 - Chiesi Limited is delighted that the Scottish Medicines Consortium (SMC) has recommended Trimbow® (beclometasone dipropionate, formoterol, glycopyrronium) as an option for use within NHS Scotland.

5.4 million people in the UK are currently receiving treatment for asthma: 1.1 million children (one in 11) and 4.3 million adults (one in 12). Around 200,000 people in the UK have severe or uncontrolled asthma.² People with uncontrolled asthma have poor symptom control and/or frequent exacerbations requiring oral corticosteroids or experience serious exacerbations requiring hospitalisation.³

"We are extremely pleased that patients in Scotland will now have an additional option to help them manage their uncontrolled asthma," said Tom Delahoyde, Managing Director of Chiesi in the UK and Ireland, Chiesi Limited. "Chiesi is committed to discovering, developing and commercialising innovative therapies to address unmet needs for those living with respiratory diseases. We will continue to work with the health technology assessment authorities to ensure that patients have access on the NHS to this important therapy."

Chiesi's triple therapy is already reimbursed in Scotland as maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a LABA and high dose of ICS, and who experienced one or more asthma exacerbations in the previous year. The inhaler also contains a dose counter that allows patients to track and manage their treatment.

###

About beclometasone dipropionate, formoterol, glycopyrronium 172/5/9 pMDI

Chiesi's triple therapy is licensed for maintenance treatment of asthma, in adult patients not adequately controlled with a maintenance combination of a LABA and a high dose of ICS, and who experienced one or more asthma exacerbations in the previous year.

For a full list of side effects and information on dosage and administration, contraindications and other precautions, please refer to <https://www.medicines.org.uk/emc/product/13816/smpc> or <https://www.emcmedicines.com/en-gb/northernireland/medicine?id=640a94c2-7fd8-440c-84b6-55607da14b1d&type=smpc> for further information.

About Chiesi Group

Based in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years' experience, operating in 30 countries with more than 6,000 employees (Chiesi Group). To achieve its mission of improving people's quality of life by acting responsibly towards society and the environment, the Group research, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE (treatment for patients with rare and ultra-rare diseases) and CARE (products and services that support specialty care and consumer-facing self-care). The Group's Research and Development centre is based in Parma and works alongside 6 other important research and development hubs in France, the U.S., Canada, China, the UK, and Sweden to pursue its pre-clinical, clinical, and regulatory programmes. Chiesi, since 2019, is the world's largest B Corp certified pharmaceutical

group. The global B Corp movement promotes business as a force for good. Moreover, Chiesi Farmaceutici S.p.A. has changed in 2018 its legal status to a Benefit Corporation, by incorporating a double purpose for the creation of shared value, and to generate value for its business, for society and the environment. As a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to include objectives of common benefit in its bylaws and to report annually in a transparent way. The Group is committed to becoming carbon neutral by the end of 2035.

Chiesi Limited is the UK & Republic of Ireland affiliate of Chiesi Group.

About B Corp®

B Corp® companies meet the highest standards of certified social and environmental performance, public transparency and legal responsibility, attempting to achieve the perfect balance between profit and sustainable objectives.

Contacts for media:

M+F Health
Rita Martins
Email rita.martins@mandfhealth.com
Phone (+44) 781786 4815

References

¹ Scottish Medicines Consortium. *Beclometasone dipropionate / formoterol / glycopyrronium 172mcg / 5mcg / 9mcg (Trimbow®)*. Available at <https://www.scottishmedicines.org.uk/medicines-advice/>. [Last accessed August 2022]

² Asthma + Lung UK. (Reviewed 2021). *What is asthma?* Available at: <https://www.asthma.org.uk/advice/understanding-asthma/what-is-asthma/>. [Last accessed August 2022].

³ Global Initiative for Asthma. (2022). *Global Strategy for Asthma Management and Prevention*. Available at: <https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf>. [Last accessed August 2022]